#1 Clinical Trials Search in Europe

Lanreotide

Lanreotide, a synthetic somatostatin analog, is being investigated in clinical trials for its potential therapeutic effects in a range of medical conditions. These trials aim to evaluate the drug’s efficacy, safety, and impact on patient outcomes across diverse areas including neuroendocrine tumors, acromegaly, polycystic kidney disease, and gastrointestinal disorders. This article summarizes key findings from recent clinical trials exploring the use of lanreotide in different patient populations.

Table of Contents

What is Lanreotide?

Lanreotide is a medication used to treat various conditions related to hormone overproduction in the body. It is known by several brand names, including Somatuline Depot, Somatuline Autogel, and Ipstyl[4]. Lanreotide belongs to a class of drugs called somatostatin analogs, which means it mimics the action of a naturally occurring hormone in the body called somatostatin[8].

Conditions Treated with Lanreotide

Lanreotide is used to treat several conditions, including:

  • Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): These are rare tumors that occur in the digestive system and pancreas. Lanreotide is used to slow down the growth of these tumors and improve symptoms[1].
  • Carcinoid Syndrome: This is a group of symptoms caused by certain types of NETs. Lanreotide can help control symptoms such as diarrhea and flushing[5].
  • Acromegaly: A condition where the body produces too much growth hormone. Lanreotide can help reduce the levels of growth hormone[9].
  • Pheochromocytoma and Paraganglioma: These are rare tumors that can cause the body to produce too many hormones called catecholamines. Lanreotide is being studied for its potential to slow down the growth of these tumors[6].

How Lanreotide Works

Lanreotide works by mimicking somatostatin, a natural hormone in the body that helps regulate various other hormones. By doing this, lanreotide can:

  • Slow down the production of certain hormones that may be overproduced in conditions like acromegaly or carcinoid syndrome
  • Reduce the growth of certain types of tumors
  • Help control symptoms associated with hormone overproduction, such as diarrhea or flushing in carcinoid syndrome

In some cases, lanreotide is being studied in combination with other medications to see if it can enhance their effects. For example, it’s being tested alongside drugs like pembrolizumab (Keytruda) for treating certain types of NETs[7].

How Lanreotide is Administered

Lanreotide is typically given as a deep subcutaneous injection. This means it’s injected under the skin, usually in the buttock area. The most common dosage is 120 mg, given once every 4 weeks (28 days)[1][2]. However, the exact dose and frequency can vary depending on the condition being treated and the individual patient’s needs. In some cases, lower doses like 90 mg may be used[7].

Current Clinical Trials

Lanreotide is currently being studied in several clinical trials for various conditions:

  • Treatment of advanced or metastatic paraganglioma and pheochromocytoma[6]
  • Combination therapy with pembrolizumab for gastroenteropancreatic neuroendocrine tumors[7]
  • Treatment of polycystic kidney disease[8]
  • Management of bile reflux in patients who have had certain types of stomach surgery[10]

These trials aim to explore new potential uses for lanreotide and to better understand its effectiveness and safety in different conditions.

Potential Side Effects

Like all medications, lanreotide can cause side effects. Common side effects may include:

  • Diarrhea
  • Abdominal pain
  • Nausea
  • Injection site reactions

More serious side effects are possible but less common. It’s important to discuss potential side effects with your healthcare provider before starting treatment with lanreotide[2].

Condition Study Design Key Findings
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) Randomized, placebo-controlled trial Lanreotide significantly prolonged progression-free survival compared to placebo
Acromegaly Phase III, randomized, open-label study Lanreotide Autogel showed efficacy in controlling IGF-1 and GH levels
Carcinoid syndrome Double-blind, randomized, placebo-controlled trial Lanreotide reduced the need for short-acting octreotide as rescue medication
Polycystic kidney disease Randomized, controlled clinical trial Investigating lanreotide’s effect on renal function decline and renal volume growth
Gastrointestinal motility disorders Pilot study Evaluating lanreotide’s impact on small bowel transit time and symptom improvement

FAQ

  • What is lanreotide and how does it work? Lanreotide is a synthetic version of somatostatin, a naturally occurring hormone in the body. It works by inhibiting the release of certain hormones and chemicals, which can help control symptoms and slow down the growth of tumors in some conditions.
  • What medical conditions is lanreotide being studied for? Lanreotide is being investigated for various conditions including gastroenteropancreatic neuroendocrine tumors (GEP-NETs), acromegaly, polycystic kidney disease, carcinoid syndrome, and gastrointestinal motility disorders.
  • How is lanreotide administered? Lanreotide is typically administered as a deep subcutaneous injection, usually in the buttock area. The dosage and frequency can vary depending on the condition being treated, but it's often given once every 4 weeks.
  • What are some common side effects of lanreotide? Common side effects of lanreotide may include injection site reactions, gastrointestinal symptoms like diarrhea or abdominal pain, and gallbladder-related issues. However, side effects can vary depending on the condition being treated and individual patient factors.
  • How long do clinical trials for lanreotide typically last? The duration of lanreotide clinical trials can vary widely depending on the study design and objectives. Some trials last for several months, while others may continue for several years to assess long-term efficacy and safety.

Ongoing Clinical Trials on Lanreotide

  • Study of Debio 4126, a new octreotide formulation, compared to placebo in patients with acromegaly who were previously treated with somatostatin analogs

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Bulgaria Denmark Estonia France +10

  • Study on the Safety and Effectiveness of Cabozantinib and Lanreotide for Patients with Gastroenteropancreatic and Thoracic Neuroendocrine Tumors

    Recruiting

    1 1 1
    Investigated drugs:
    Italy

  • Study on RYZ101 for Patients with Advanced Gastroenteropancreatic Neuroendocrine Tumors After Previous Treatment

    Recruiting

    1 1 1 1
    Investigated drugs:
    Belgium France The Netherlands Spain

  • Study on the Safety of Lanreotide and Metformin for Patients with Advanced Gastrointestinal or Lung Carcinoids

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study on the Effect of Octreotide and Lanreotide in Peptide Receptor Radionuclide Therapy for Adults with Neuroendocrine Tumors

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on Continuing Somatostatin Analogues with Sunitinib, Octreotide, and Lutetium (177Lu) Oxodotreotide for Patients with Neuroendocrine Tumors

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium The Netherlands

  • Study on the Effectiveness and Safety of CAM2029 Compared to Octreotide and Lanreotide in Patients with Gastroenteropancreatic Neuroendocrine Tumors

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Belgium France Germany Hungary Italy The Netherlands +2

Glossary

  • Acromegaly: A hormonal disorder that develops when the pituitary gland produces too much growth hormone during adulthood, leading to the enlargement of bones and soft tissues.
  • Carcinoid syndrome: A group of symptoms associated with carcinoid tumors, which can include flushing, diarrhea, and heart problems.
  • Gastroenteropancreatic neuroendocrine tumors (GEP-NETs): Rare tumors that form in the digestive system, including the pancreas, and can produce excess hormones.
  • Somatostatin: A hormone that regulates the endocrine system and affects neurotransmission and cell proliferation.
  • Subcutaneous injection: An injection that delivers medication into the layer of tissue between the skin and the muscle.
  • Progression-free survival: The length of time during and after treatment that a patient lives with the disease but it does not get worse.
  • RECIST criteria: Response Evaluation Criteria in Solid Tumors, a standard way to measure how well a cancer patient responds to treatment.
  • Polycystic kidney disease: A genetic disorder characterized by the growth of numerous cysts in the kidneys.
  • Gastrointestinal motility disorder: A condition that affects the movement of muscles in the digestive system, leading to various digestive symptoms.
  • Insulin-like growth factor 1 (IGF-1): A hormone similar in structure to insulin that plays an important role in growth and development.

References

  1. https://clinicaltrials.gov/study/NCT03083210
  2. https://clinicaltrials.gov/study/NCT02823691
  3. https://clinicaltrials.gov/study/NCT02288377
  4. https://clinicaltrials.gov/study/NCT01731925
  5. https://clinicaltrials.gov/study/NCT00774930
  6. https://clinicaltrials.gov/study/NCT03946527
  7. https://clinicaltrials.gov/study/NCT03043664
  8. https://clinicaltrials.gov/study/NCT01616927
  9. https://clinicaltrials.gov/study/NCT01861717
  10. https://clinicaltrials.gov/study/NCT02054637